Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Submission Following Regulatory Feedback
Nutriband Inc. has received critical FDA guidance confirming the regulatory pathway for its AVERSA™ Fentanyl abuse-deterrent transdermal system, marking a significant step forward in addressing the opioid crisis through innovative pharmaceutical technology.
Nutriband Inc. (NASDAQ: NTRB) has received final meeting minutes from its September 18, 2025, virtual meeting with the U.S. Food and Drug Administration regarding its lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. The meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine confirmed the regulatory pathway as a 505(b)(2) New Drug Application and provided guidance on the reference listed drug and bridging strategy.
The FDA feedback represents a crucial milestone in advancing a potential solution to the ongoing opioid crisis. AVERSA™ technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, addressing a critical public health concern. The technology can be incorporated into any transdermal patch, offering broad application potential beyond fentanyl specifically.
During the regulatory meeting, the FDA provided specific feedback on manufacturing validation, product specifications, and stability testing requirements. The agency also outlined expectations for in vitro manipulation and extraction studies needed to characterize AVERSA's abuse-deterrent properties for potential NDA submission. This detailed guidance helps streamline the development process and clarifies the regulatory expectations for demonstrating the product's safety and effectiveness.
The 505(b)(2) regulatory pathway allows Nutriband to rely on existing data for approved fentanyl products while demonstrating the unique abuse-deterrent properties of their AVERSA technology. This approach can potentially accelerate the development timeline while maintaining rigorous safety standards. The company's progress can be tracked through their corporate communications available at https://ibn.fm/NTRB.
As a developer of prescription transdermal pharmaceutical products, Nutriband's advancement of AVERSA™ Fentanyl comes at a critical time when healthcare providers and regulators are seeking innovative solutions to combat prescription drug abuse. The successful development of abuse-deterrent formulations represents an important strategy in balancing legitimate medical needs for pain management with public health protection against opioid misuse.
The regulatory clarity provided by the FDA meeting positions Nutriband to move forward with greater confidence in their development strategy. The company's website at https://www.nutriband.com provides additional corporate information, though investors should note that website content is not formally part of the regulatory submission process. The continued development of AVERSA™ technology represents an important innovation in pharmaceutical safety that could have significant implications for pain management practices and public health outcomes.